Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Ipsen (IPSEY) announced confirmation of an expanded collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) in advanced pancreatic neuroendocrine tumors or pNETs and advanced extra-pancreatic neuroendocrine tumors or epNETs.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1935927066-73c9875f00f341659ec4f575bd9c8eeb.jpg "How Google (Alphabet) Makes Money: Advertising and Cloud")
:max_bytes(150000):strip_icc():format(jpeg)/paperworkmortgagestress-c0cd32dc997a4720805d2d1cb8bcc1ad.jpg "7 Solutions for Homeowners Struggling With Their Mortgage")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1847970758-2834153353e0467b9dbafcb5e2feb262.jpg "Roadside Assistance Insurance: What It Is, How It Works")